MOUNTAIN VIEW, Calif., May 10 VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of May.
Advertisement
A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.
About VIVUS
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, QnexaŽ, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSEŽ (alprostadil), a first generation therapy for the treatment of erectile dysfunction, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
Advertisement
The conference presentation schedule is as follows: The Ninth Annual JMP Securities Research Conference Presented by: Timothy Morris, chief financial officer May 11, 2010 at 3:30 p.m. PDT Ritz Carlton, San Francisco, CA Bank of America Merrill Lynch Health Care Conference Presented by: Timothy Morris, chief financial officer May 13, 2010 at 10:00 a.m. EDT The Grand Hyatt, New York, NY Rodman & Renshaw 6th Annual Global Healthcare Conference Presented by: Barbara Troupin, M.D., senior director medical affairs May 18, 2010 at 3:15 p.m. BST Grosvenor House Hotel, London, UK 2010 Citi Investment Research Global Health Care Conference Presented by: Timothy Morris, chief financial officer May 26, 2010 at 1:30 p.m. EDT Grand Hyatt, New York, NY
SOURCE VIVUS, Inc.
